Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of the Poly(ADP-ribose) Polymerase (PARP) Inhibitor Veliparib (ABT-888) in Combination with Irinotecan in Patients with Advanced Solid Tumors (Q37059846)
Jump to navigation
Jump to search
scientific article published on 03 February 2016
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of the Poly(ADP-ribose) Polymerase (PARP) Inhibitor Veliparib (ABT-888) in Combination with Irinotecan in Patients with Advanced Solid Tumors |
scientific article published on 03 February 2016 |
Statements
1 reference
Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of the Poly(ADP-ribose) Polymerase (PARP) Inhibitor Veliparib (ABT-888) in Combination with Irinotecan in Patients with Advanced Solid Tumors (English)
1 reference
Sara M Tolaney
1 reference
Patricia M LoRusso
1 reference
Jing Li
1 reference
Angelika Burger
1 reference
Lance K Heilbrun
1 reference
Edward A Sausville
1 reference
Scott A Boerner
1 reference
Daryn Smith
1 reference
Mary Jo Pilat
1 reference
Jie Zhang
1 reference
James M Cleary
1 reference
Alice P Chen
1 reference
Lawrence Rubinstein
1 reference
Julie L Boerner
1 reference
Adam Bowditch
1 reference
Dongpo Cai
1 reference
Tracy Bell
1 reference
Andrew Wolanski
1 reference
Allison M Marrero
1 reference
Yiping Zhang
1 reference
Jiuping Ji
1 reference
Katherine Ferry-Galow
1 reference
Robert J Kinders
1 reference
Ralph E Parchment
1 reference
Geoffrey I Shapiro
1 reference
3 February 2016
1 reference
1 reference
3227-3237
1 reference
1 reference
1 reference
1 reference
1 reference
Identifiers
1 reference
1 reference
1 reference